EUVIMEDEUVIMED entdecken
Open Access

Factors Influencing Relapse After Omalizumab in Chronic Urticaria. Does the Method of Discontinuation Influence Relapse?

Petek Üstün, Esra Adışen

Dermatology Practical & Conceptual · 31.07.2025 · 15 (3) · 5196

DOI: 10.5826/dpc.1503a5196 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatology Practical & Conceptual, online erschienen am 31.07.2025. Verfasst von Petek Üstün und 1 weiteren Autor:innen. Beteiligte Einrichtung: Deparment of Dermatology, Aksaray Training and Research Hospital, Aksaray, Turkey. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Omalizumab is recommended until spontaneous remission occurs rather than for a specific period of time in chronic urticaria (CU). The rate of recurrence of symptoms after treatment varies depending on the method of discontinuation.

Objectives

Our study aimed to investigate how the method of omalizumab discontinuation, as well as other factors, affects the rate of post-treatment relapses.

Methods

Patients with CU were divided into 3 groups based on their method of discontinuing omalizumab treatment: direct discontinuation, extending treatment intervals to 8 weeks, and reducing the treatment dose to 150 mg/4 weeks. These groups were then compared for relapse rates.

Results

A total of 200 patients were included in this study. Among the 109 patients who discontinued omalizumab directly, 65.1% experienced a relapse. The relapse rate was 40.7% in those who extended the treatment interval to 8 weeks, and 15.6% in those who reduced the dose to 150 mg/4 weeks. There was a statistically significant difference in post-treatment relapse rates according to the method of discontinuation (p < 0.001).

Conclusions

Gradual tapering of treatment rather than direct discontinuation has been shown to prolong remission. Achieving the lowest relapse rate with a reduction of the treatment dose to 150 mg/4 weeks is significant for the design of omalizumab discontinuation protocol and provides insight for future studies.

Autor:innen und Institutionen

  • Deparment of Dermatology, Aksaray Training and Research Hospital, Aksaray, Turkey.
  • Deparment of Dermatology, Gazi University Faculty of Medicine, Ankara, Turkey.

Zitieren

APA

Üstün, P., & Adışen, E. (2025). Factors Influencing Relapse After Omalizumab in Chronic Urticaria. Does the Method of Discontinuation Influence Relapse?. Dermatology Practical & Conceptual, 15(3), 5196. https://doi.org/10.5826/dpc.1503a5196

Vancouver

Üstün P, Adışen E. Factors Influencing Relapse After Omalizumab in Chronic Urticaria. Does the Method of Discontinuation Influence Relapse?. Dermatology Practical & Conceptual. 2025;15(3):5196. doi:10.5826/dpc.1503a5196

BibTeX
@article{stn2025,
  author = {Üstün, Petek and Adışen, Esra},
  title = {Factors Influencing Relapse After Omalizumab in Chronic Urticaria. Does the Method of Discontinuation Influence Relapse?},
  journal = {Dermatology Practical & Conceptual},
  year = {2025},
  volume = {15},
  number = {3},
  pages = {5196},
  doi = {10.5826/dpc.1503a5196}
}
Kostenlos starten →